Clinical trials: Multiple Chronic Diseases
Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
This phase II trial studies how well reduced intensity donor stem cell transplant works in treating patients with hematologic malignancies.
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
- Trial name
- NCT01384513
- Testing
- Fludarabine, Busulfan, Total Body Irradiation (TBI)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Leukemia, B-cell Leukemia
Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia
The primary objective of this study was to evaluate the safety and efficacy of the combination of fludarabine and cyclophosphamide in previously untreated CLL patients.
- Conditions
- Leukemia, B-cell Leukemia, Chronic Leukemia, Chronic Lymphocytic Leukemia (CLL)
- Trial name
- NCT00230282
- Testing
- Alemtuzumab, Fludarabine, Cytoxan
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Steven E. Coutre
Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
A Study of the Effectiveness of Fampridine in Improving Upper Limb Function in MS
The purpose of this study is to examine the effect of treatment with fampridine in patients with secondary progressive MS (SPMS) or primary progressive MS (PPMS) with upper limb dysfunction (as defined by a 9-HPT time of between…
- Trial name
- NCT02208050
- Testing
- Fampridine
- Where
- 2 sites in Ireland
- Volunteers
- 64 people
- Sponsor
- University College Dublin
Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma
This clinical trial studies peripheral blood hemapoietic stem cell mobilization with the combination of bortezomib and G-CSF (filgrastim) in multiple myeloma and non-Hodgkin lymphoma patients.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT02037256
- Testing
- bortezomib, filgrastim, autologous hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
End-Stage Renal Disease
Anti-Cytokine Therapy for Hemodialysis InflammatION
Anti-Cytokine Therapy for Hemodialysis InflammatION (ACTION) is a phase II multi-center study to evaluate the safety and tolerability of anakinra, an IL-1 receptor antagonist, for patients treated with maintenance hemodialysis.
- Trial name
- ACTION (NCT03141983)
- Testing
- Anakinra
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- University of Pennsylvania
Chronic Spontaneous Urticaria
A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.
The purpose of this study was to establish efficacy and safety of ligelizumab in adolescent and adult subjects with CSU who remained symptomatic despite standard of care treatment by demonstrating better efficacy over omalizumab…
- Trial name
- NCT03580356
- Testing
- Ligelizumab, Omalizumab
- Where
- 183 sites in United States, Argentina and 25 more
- Volunteers
- 1,078 people
- Sponsor
- Novartis Pharmaceuticals
Anemia
A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.
This study will evaluate the efficacy and safety of different subcutaneous starting doses and dosing frequencies of Mircera in anemic patients with chronic kidney disease not yet on dialysis.
- Trial name
- NCT00048048
- Testing
- methoxy polyethylene glycol-epoetin beta [Mircera]
- Where
- 15 sites in United States, Canada and 3 more
- Volunteers
- 65 people
- Sponsor
- Hoffmann-La Roche
Chronic Shift Work Sleep Disorder
Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL
The purpose of the study is to compare the overnight efficacy and plasma concentration-time profiles of armodafinil and PROVIGIL, after multiple doses, in patients with excessive sleepiness associated with chronic Shift Work…
- Trial name
- NCT00236080
- Testing
- PROVIGIL 200 mg, Armodafinil 250 mg, Armodafinil 200 mg
- Where
- 20 sites in United States
- Volunteers
- 136 people
- Sponsor
- Cephalon
Multiple Myeloma, Non-Hodgkin Lymphoma
Phase I Study of OPB-51602 in Patients With Hematologic Malignancies
To determine the maximum tolerated dose (MTD) of OPB-51602
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Acute Lymphoid Leukemia
- Trial name
- NCT01344876
- Testing
- OPB-51602
- Where
- 2 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Chronic Graft-versus-host Disease
Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)
To assess the efficacy of R348 Ophthalmic Solutions administered for 12 weeks to subjects evaluated by objective and subjective measures.
- Trial name
- DROPS-2 (NCT02040623)
- Testing
- R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Rigel Pharmaceuticals
Fabry Disease, Chronic Kidney Disease, Stage IV (Severe)
Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme
This study was designed to determine appropriate treatment with Fabrazyme at a biweekly dose of either 1 mg/kg or 3 mg/kg in a population of patients with severe renal disease burden.
- Trial name
- NCT00837824
- Testing
- Fabrazyme (agalsidase beta)
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- Genzyme, a Sanofi Company
COPD
Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD
This is an open-label, multi-center study to evaluate the accuracy, reliability and functionality of the Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) dose indicator in adult subjects with moderate to…
- Trial name
- NCT02268396
- Testing
- Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler
- Where
- 10 sites in United States
- Volunteers
- 138 people
- Sponsor
- Pearl Therapeutics, Inc.
COPD
Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects with Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- Trial name
- NCT02536508
- Testing
- BGF MDI 320/14.4/9.6 μg, GFF MDI 14.4/9.6 μg, BFF MDI 320/9.6 μg
- Where
- 64 sites in United States
- Volunteers
- 627 people
- Sponsor
- Pearl Therapeutics, Inc.
Pulmonary Disease, Chronic Obstructive
A Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses of Inhaled GSK2269557 in Adults With Persistent, Uncontrolled Asthma
This study is a multi-centre, randomised, double-blind, placebo-controlled (with rescue medication), two period crossover study in subjects with persistent uncontrolled asthma, currently not treated with an inhaled corticosteroid…
- Trial name
- NCT02567708
- Testing
- GSK2269557 DPI
- Where
- 12 sites in Germany
- Volunteers
- 50 people
- Sponsor
- GlaxoSmithKline
Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19
A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection
This is a Phase 2, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken once daily at bedtime for the management…
- Conditions
- Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID, Long Haul COVID
- Trial name
- PREVAIL (NCT05472090)
- Testing
- TNX-102 SL
- Where
- 29 sites in United States
- Volunteers
- 63 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Acute Leukemia, Chronic Leukemia
Nonmyeloablative Haploidentical Transplant Followed by MLN9708
In an attempt to reduce relapse risk and improve outcomes following haploidentical transplantation for patients with high risk hematologic malignancies, the investigators will implement several strategies to augment the well…
- Conditions
- Acute Leukemia, Chronic Leukemia, Myelodysplastic Syndrome, Lymphomas
- Trial name
- NCT02169791
- Testing
- MLN9708
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Northside Hospital, Inc.
Chronic Hepatitis C
A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects
The primary purpose of this study is to assess the change in Hepatitis C Virus RNA during dosing with daclatasvir and during the follow-up period in subjects with chronic hepatitis C infection
- Trial name
- NCT00663208
- Testing
- Daclatasvir
- Where
- 8 sites in United States, Puerto Rico
- Volunteers
- 167 people
- Sponsor
- Bristol-Myers Squibb
Psoriasis
Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis
The purpose of this study is to determine whether teplizumab is safe when administered subcutaneously (by needle under the skin) in subjects with psoriasis.
- Trial name
- NCT00954915
- Testing
- teplizumab
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- MacroGenics
Multiple Sclerosis
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the disability of patients suffering from progressive multiple sclerosis and especially those with gait impairment.
- Trial name
- SPI2 (NCT02936037)
- Testing
- MD1003 100mg capsule
- Where
- 92 sites in United States, Australia and 11 more
- Volunteers
- 642 people
- Sponsor
- MedDay Pharmaceuticals SA
Multiple Myeloma
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to assess the safety and benefits of the investigational study drug, KW-2478, when given with bortezomib (Velcade®), a drug approved for the treatment of Multiple Myeloma (MM).
- Trial name
- NCT01063907
- Testing
- KW-2478, Bortezomib
- Where
- 26 sites in United States, Philippines and 1 more
- Volunteers
- 95 people
- Sponsor
- Kyowa Kirin Co., Ltd.